A durable OTC/private-label leader priced like a distressed asset—PRGO’s upside hinges on divestitures and rapid deleveraging while defending margins amid tariffs and soft demand.
Overview
Perrigo (PRGO) is a pure-play global consumer self-care company built around an intentionally “barbell” portfolio: highly cash-generative U.S. store-brand OTC leadership funding investment in higher-margin, recognized brands internationally and in select U.S. categories. The company’s modern identity is the product of a multi-year pivot away from legacy complexity and leverage—particularly after the $7B Elan deal (2013) and subsequent divestments of generic Rx and animal health—to focus on OTC medicines, wellness, and adjacent self-care. Operations are split into (1) Consumer Self-Care Americas (CSCA), the core earnings engine (~two-thirds of sales historically) and the dominant supplier of U.S. private-label OTC (over half of domestic store-brand volume across upper respiratory, pain/sleep, digestive, nutrition/infant formula, oral care, skin, and women’s health), and (2) Consumer Self-Care International (CSCI), where value is driven more by localized consumer brands and where Perrigo ranks among the top 10 OTC companies in Europe with brands such as Compeed, Solpadeine, Coldrex, EllaOne, Physiomer, and Jungle Formula. PRGO’s model spans virtually all consumer price points and over 100 molecular compounds, pairing premium innovation (e.g., Opill—first daily OTC birth control pill in the U.S.) with affordable store-brand equivalents. A central structural issue is customer concentration: the top ten customers contribute ~46–47% of sales and Walmart alone ~11.8%, giving retailers significant negotiating leverage. The investment debate therefore revolves around whether PRGO can execute its turnaround, simplify the portfolio, and delever—while sustaining share gains in a soft OTC consumption environment.